Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind placebo-controlled study of GR1802 injection in chronic spontaneous urticaria
CTR20250174Phase 3Completed
- Sponsor
- Zhixiang Jintai
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of telikibart in chronic idiopathic urticaria (CIU), sponsored by Zhixiang Jintai. Started Mar 2025; status: completed.
02
Drugs
telikibart
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on CTR20250174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250174.